Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cerep licenses eye disease compound to Thea

This article was originally published in Scrip

Executive Summary

Cerep has licensed an LFA-1 receptor antagonist with potential for treating eye disease to Théa for an undisclosed sum. Last year the two firms identified a new topical indication for the antagonist in ophthalmology which greatly reduces the risk of hepatotoxic effects. Bristol-Myers Squibb and Cerep stopped the original development programme in systemic immuno-inflammatory diseases after discovering hepatotoxic effects following oral administration. The licence agreement triggers a first payment to Cerep, followed by milestones and royalties once the drug reaches the market. Cerep will receive the first milestone after successful proof-of-concept, which will be started shortly. Thierry Jean, Cerep'spresident and CEO, said the new indication should reduce side-effects as it would most likely require a reduced dosage. LFA-1 is a key adhesion receptor in immune and inflammatory processes and acts as a signal-transducing molecule.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007666

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel